Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study

Published 2019 View Full Article

Authors

Keywords

Alectinib, non-small-cell lung cancer, ALEX, EML4-ALK, NGS

Journal

Journal of Thoracic Oncology

Volume -, Issue -, Pages -

Publisher

Elsevier BV

Online

2019-03-20

DOI

10.1016/j.jtho.2019.03.007

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started